Accepted for Publication: July 1, 2011.
Published Online: September 12, 2011. doi:10.1001/archneurol.2011.243
Author Contributions: Dr Naismith had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Naismith and Xu contributed equally as co–first authors. Drs Song and Cross contributed equally as co–senior authors. Study concept and design: Naismith, Song, and Cross. Acquisition of data: Naismith, Xu, Tutlam, and Lancia. Analysis and interpretation of data: Naismith, Xu, Trinkaus, and Cross. Drafting of the manuscript: Naismith. Critical revision of the manuscript for important intellectual content: Xu, Tutlam, Lancia, Trinkaus, Song, and Cross. Statistical analysis: Trinkaus. Obtained funding: Naismith and Song. Administrative, technical, and material support: Naismith, Xu, Tutlam, Lancia, Song, and Cross. Study supervision: Cross.
Financial Disclosure: Dr Naismith has received travel expenses and/or honoraria for lectures, educational activities, and consulting from Acorda Therapeutics, Bayer Healthcare, Biogen Idec, EMD Serono, Genzyme Corporation, Teva Neurosciences; he receives research support from Acorda Therapeutics, and the National Institutes of Health (NIH; grant K23NS052430-01A1 [principal investigator]). Dr Cross serves on scientific advisory boards for Eli Lilly and Company, Genentech Inc, and Biogen Idec; serves on the editorial boards of Brain Pathology and the Journal of Neuroimmunology and as an editor and contributor to CONTINUUM ; receives royalties from the publication of Handbook of Multiple Sclerosis, 4th ed (Taylor & Francis Group, 2006); serves on speakers' bureaus for Bayer Schering Pharma, Biogen Idec, and Teva Neurosciences; has received speaker honoraria from Amgen and Pfizer Inc; and receives research support from sanofi-aventis, Acorda Therapeutics, Genentech Inc, Biogen Idec, the NIH and the National Institute of Neurological Disorders and Stroke (grants PO1 NS059560-01 [principal investigator], UO1 NS45719-01A1 [coinvestigator], RO1 NS047592 [coinvestigator], and RO1 NS 051591 [principal investigator]), Washington University Institute of Clinical and Translational Sciences, the National Multiple Sclerosis Society, the Consortium of Multiple Sclerosis Centers, and the Barnes-Jewish Hospital Foundation.
Funding/Support: This study was supported by the NIH (grants K23NS052430-01A1 and K12RR02324902 to Dr Naismith and grant K24 RR017100 to Dr Cross), the National Multiple Sclerosis Society (grant FG1782A1 to Dr Xu, grant CA1012 to Drs Cross and Song, and grant RG 3670 to Dr Song), and the Manny and Rosalyn Rosenthal–Dr John L. Trotter Chair in Neuroimmunology from the Barnes-Jewish Hospital Foundation (Dr Cross). This study was made possible by grant UL1 RR024992 from the National Center for Research Resources, a component of the NIH and the NIH Roadmap for Medical Research. This research was also supported in part by NIH grants CO6 RR020092 and RR024992 (to the Washington University Institute of Clinical and Translational Sciences Brain, Behavioral, and Performance Unit).
Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the opinions of the National Center for Research Resources or the NIH.